Clinical Evidence

Clinical studies have demonstrated the safety, efficacy and ease of use of Control-IQ+ Technology

Control-IQ+ Technology

Control-IQ Technology

2025 – One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study
2025 – Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different CGM Sensors. Journal of Diabetes Science and Technology
2025 – Automated Insulin Delivery in Older Adults with Type 1 Diabetes
2024 – Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study.
2024 - Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with Control-IQ technology
Apr 2023 – A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72
2023 - Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes
2023 – Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial.
Nov 2022 - Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis
Apr 2021 - Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Mar 2021 - One Year Real-World Use of Control-IQ Advanced Hybrid Closed-Loop Technology
Feb 2021 - A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes
Jan 2021 - Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Dec 2020 - Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Aug 2020 - A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
May 2020 - Glycemic Outcomes of Use of Closed-Loop Control vs PLGS on Type 1 Diabetes: A Randomized Controlled Trial
Oct 2019 - Six-Month Randomized, Multi-Center Trial of Closed-Loop Control in Type 1 Diabetes

Basal-IQ Technology

Important Safety Information

RX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog, Humalog, or Lyumjev U-100 insulin.

t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.

Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.

Warning: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.

Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

Important Safety Information

RX ONLY. The t:slim X2 pump and Basal-IQ technology are intended for single patient use for the management of diabetes mellitus in persons 6 years of age and greater. The t:slim X2 pump and Basal- IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.

Basal-IQ technology: Basal-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and alternate controller enabled (ACE) pump to automatically suspend delivery of insulin based on iCGM readings and predicted glucose values. The bolus calculator is indicated for the management of diabetes by people with diabetes by calculating an insulin dose or carbohydrate intake based on user entered data. Users of the t:slim X2 pump and Basal-IQ technology must: be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.